Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Business Segments — Other Nonoperating Income (Expense)

Similar metrics at other companies

Dollar Tree logo
DLTRReportable Segment — Other Nonoperating Income (Expense)
$5.4M-91.2%
comScore logo
SCORReportable Segment — Other Nonoperating Income (Expense)
-$717K-108%
Rimini Street, Inc. logo
RMNIReportable Segment — Other Nonoperating Income (Expense)
-$1.24M-1,510%
Nextpower Inc. logo
NXTReportable Segment — Other Nonoperating Income (Expense)
$6.39M+11.9%
ITG
ITGRReportable Segment — Other Nonoperating Income (Expense)
-$13.3M-1,411%
Global Industrial logo
GICReportable Segment — Other Nonoperating Income (Expense)
$100K+200%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$705.48M+12.4%
Enterprise value$561.65M-12.6%
P/E12.1×-225×
P/S5.2×-4.9×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Other segment items:
Impairment of intangible assets58,71058,710
Income tax expense4,0422,19910,9573,381
Interest income(1,477)(2,257)(3,661)(2,975)
Depreciation and amortization expense3161,6517323,300
Interest expense2,0091,7113,978
Other income, net (a)6,985(135,353)(26,718)(138,738)
Segment net income$8,752$74,707$46,642$71,608

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s business segments — other nonoperating income (expense)?
Zevra Therapeutics, Inc. (ZVRA) reported business segments — other nonoperating income (expense) of -$6.99M in Q2 2026.
How has Zevra Therapeutics, Inc.'s business segments — other nonoperating income (expense) changed year-over-year?
Zevra Therapeutics, Inc.'s business segments — other nonoperating income (expense) decreased by 105.2% year-over-year, from $135.35M to -$6.99M.
What does business segments — other nonoperating income (expense) mean?
Includes miscellaneous income or expenses that fall outside the scope of the segment's primary operating activities, such as gains or losses from asset sales or currency fluctuations. This metric helps isolate core operational performance from transient or non-recurring financial events.

Ask your AI about Zevra Therapeutics, Inc.'s business segments — other nonoperating income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude